Supreme Court Issues Mixed Ruling on Biotech-Drug Copies
The U.S. Supreme Court stands in Washington, D.C., U.S., on Monday, June 27, 2016. A divided U.S. Supreme Court struck down a Texas law that had threatened to close three-quarters of the states abortion clinics by putting new requirements on facilities and doctors.
Photographer: Andrew Harrer/BloombergThis article is for subscribers only.
The U.S. Supreme Court issued a mixed decision on the rules governing efforts to get low-cost alternatives to pricey biotechnology drugs on the market.
The justices said patent holders can’t use federal law to enforce a requirement that companies seeking to sell “biosimilars” provide information about their product. The unanimous court, however, said patent holders might be able to use state law to accomplish the same goal.